Biosimilar Guidance Puts BLA Sponsors On The Spot To Defend Reference Product Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA draft guidance specifies what information a BLA sponsor must submit to show its product is entitled to period of exclusivity that limits FDA review or licensing of a biosimilar application.
You may also be interested in...
Sandoz’s Biosimilar Filing Is Culmination Of Paradigm Shift In FDA Drug Review
FDA clinical reviewers moved from traditional “new drug” review mode to determining the evidence needed to demonstrate a follow-on product is highly similar to the reference biologic, Sandoz exec says, describing firm’s interactions with FDA on its filgrastim 351(k) application.
FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics
The agency’s first three draft guidances on biosimilar product development describe how to characterize biosimilar and reference products and extrapolate data on one condition of use to another. FDA says interchangeability is difficult to determine now and will require a switching study.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.